Evolution of Pulmonary Capillary Blood Volume

Evolution of Pulmonary Capillary Blood Volume (Vc) in Patients After a First Episode of Pulmonary Embolism.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00941187

Acronym

VcEP

Enrollment

Registered

2009-07-17

Start date

2009-08-31

Completion date

2012-12-31

Last updated

2013-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Keywords

pulmonary embolism, pulmonary capillary blood volume, double diffusion NO/CO method

Brief summary

The purpose of this monocentric, preliminary study is to assess the evolution of pulmonary capillary blood volume (Vc), measured by the double diffusion nitric oxide/carbon monoxide (NO/CO) method (Guenard et al.; Respir Physiol 1987), from the starting of the anticoagulant therapy to 6 months after, and to search correlations with the evolution of clinical (dyspnea and results of the 6 minutes walking test), biological (BNP; Troponin), echocardiographic (right ventricular dysfunction, pulmonary arterial pressure) and ventilation/perfusion lung scan data.

Interventions

OTHERdiffusion NO/CO method

pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Patient with a first episode of symptomatic pulmonary embolism, treated with anticoagulant * Age from 18 to 75 years-old

Exclusion criteria

* Confirmed pulmonary embolism in the past * Massive pulmonary embolism, thrombolytic treatment * Confirmed left heart systolic dysfunction * Confirmed asthma, chronic obstructive pulmonary disease or pulmonary fibrosis * Expected life below 6 months * Pleural effusion with indication of evacuation * Bronchopulmonary cancer * Pulmonary surgery with resection of two lobes minimum * Predictable incapacity to complete the 6 minutes walking test

Design outcomes

Primary

Measure	Time frame
difference of pulmonary capillary blood volume (Vc) from J0 to 6 months	from the starting of the anticoagulant therapy to 6 months after

Secondary

Measure	Time frame
correlations with the evolution of clinical (dyspnea and results of the 6 minutes walking test), biological (BNP; Troponin), echocardiographic (right ventricular dysfunction, pulmonary arterial pressure) and ventilation/perfusion lung scan data	from the starting of the anticoagulant therapy to 6 months after

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026